Featured Videos

ORLANDO, FL USA (UroToday.com) - Dr. Malte Rieken presented predictors of cancer-specific mortality (CSM) from recurrent penile squamous cell carcinoma after primary surgical therapy. He reviewed retrospective data on 314 patients who had a recurrence over the course of 63 years. Thirty percent underwent inguinal lymphadenectomy and 41% of the patients had adjuvant radiation. Most patients with recurrence had a local recurrence, and 10% had distal metastasis. auaThere as a 10.5 month median time to recurrence in this cohort, and on regression analysis, shorter time to recurrence, regional and distal recurrence, and nodal status were predictors of poor outcome.

Overall, this data might be used to risk stratify patients at the time of recurrence to help guide decisions regarding further therapy in the context of patient comorbidities.

Presented by Malte Rieken at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

New York, NY USA

Written by Phillip Abbosh, MD, PhD, medical writer for UroToday.com

 

Clinical Trials
Searchable data base of currently enrolling clinical trials
Journals
Publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 3 Issue 2

Everyday Urology™ - Oncology Insights

From the Editor

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe

Calendar
Upcoming educational events
November 23-25, 2018 / European Society for Medical Oncology Asia 2018 Congress
European Society for Medical Oncology Asia 2018 Congress
November 25-30, 2018 / RSNA 2018 Annual Meeting
RSNA 2018 Annual Meeting